Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02149264 · ClinicalTrials.gov registry record · Phase 3

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males

A Phase 3 study, sponsored by Ferring Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
160
Enrollment target

NCT02149264 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 160 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02149264, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
160 participants
Enrollment target

Study Summary

This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and safety of FE 999303 (Testosterone gel) in adult hypogonadal males.

Interventions

  • DRUG Testosterone gel (FE 999303)

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2014-07
Est. Completion 2015-06
Phase Phase 3

Sponsor

Ferring Pharmaceuticals

83 total trials

What the Registry Record Tells You About NCT02149264

The ClinicalTrials.gov registry entry for NCT02149264 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Testosterone gel (FE 999303) is the first listed.

NCT02149264 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02149264 about?

NCT02149264 is a clinical study titled "A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males". This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and safety of FE 999303 (Testosterone gel) in adult hypogonadal males.

What is the current status of trial NCT02149264?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2014-07. Estimated completion is 2015-06.

What interventions are being tested in trial NCT02149264?

The interventions under investigation include: Testosterone gel (FE 999303) (DRUG).

Who is sponsoring clinical trial NCT02149264?

This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.